Glioblastoma (GBM) is an aggressive central nervous system tumor with a poor prognosis. this study was conducted to determine any comorbid medical conditions that are associated with survival in GBM. Data were collected from medical records of all patients who presented to VcU Medical center with GBM between January 2005 and February 2015. Patients who underwent surgery/biopsy were considered for inclusion. cox proportional hazards regression modeling was performed to assess the relationship between survival and sex, race, and comorbid medical conditions. 163 patients met inclusion criteria. comorbidities associated with survival on individual-characteristic analysis included: history of asthma (Hazard Ratio [HR]: 2.63; 95% Confidence Interval [CI]: 1.24-5.58; p = 0.01), hypercholesterolemia (HR: 1.95; 95% CI: 1.09-3.50; p = 0.02), and incontinence (HR: 2.29; 95% CI: 0.95-5.57; p = 0.07). History of asthma (HR: 2.22; 95% CI: 1.02-4.83; p = 0.04) and hypercholesterolemia (HR: 1.99; 95% CI: 1.11-3.56; p = 0.02) were associated with shorter survival on multivariable analysis. Surgical patients with GBM who had a prior history of asthma or hypercholesterolemia had significantly higher relative risk for mortality on individual-characteristic and multivariable analyses.
Results
A total of 197 patients diagnosed with GBM presented to VCU from January 2005 to February 2015. Of those, 163 patients met criteria for inclusion. The 34 patients who did not meet inclusion criteria were excluded primarily due to missing tumor location, missing extent of resection, or missing both variables. Table 1 lists the frequency of demographic and clinical characteristics within the study sample. There were 95 (58%) male patients. The mean age at time of diagnosis was 61.7 ± 13.3 years. A total of 124 (76%) patients identified as white race. Following surgery, 61 (37%) patients had complete tumor resection, 36 (22%) had near total resection, and 22 (14%) had subtotal resection.
At the time of data collection, 147 (90%) patients were deceased, 15 (9%) patients were lost to follow-up, and 1 (1%) patient was alive. The overall probability of survival in our sample was 71% at six months, 50% at twelve months, 34% at eighteen months, and 26% at twenty-four months. Figure 1 shows a Kaplan-Meier survival curve of the overall sample. Table 2 demonstrates the frequency of pre-existing medical comorbidities. The most common comorbidities were: hypertension (35%), diabetes (13%), and heart disease (10%). Table 3 presents the results of the analyses for demographics, clinical characteristics, and medical comorbidities while controlling for age, EOR, and tumor location. Prior history of asthma (hazard ratio [HR]: 2.63; 95% confidence interval [CI]: 1.24-5.58; p = 0.01), hypercholesterolemia (HR: 1.95; 95% CI: 1.09-3.50; p = 0.02), and urinary incontinence (HR: 2.29; 95% CI: 0.95-5.57; p = 0.07) were associated with shorter overall survival (p < 0.15), while controlling for age, tumor location, and EOR. The final multivariable model included age, tumor location, EOR, asthma, hypercholesterolemia, and urinary incontinence ( Table 4 ). Multivariable analysis demonstrated that increasing age (HR: 1.02; 95% CI: 1.01-1.04; p < 0.01), asthma (HR: 2.22; 95% CI: 1.02-4.83; p = 0.04), and hypercholesterolemia (HR: 1.99; 95% CI: 1.11-3.56; p = 0.02) were each associated with shorter overall survival. Urinary incontinence was not associated with survival (HR: 1.96; 95% CI: 0.78-4.92; p = 0.15) in the multivariable model. Complete resection (HR: 0.52; 95% CI: 0.34-0.80, p < 0.01) and near total resection (HR: 0.58; 95% CI: 0.35-0.94; p = 0.03) were both associated with significantly longer survival time when compared to biopsy alone, while subtotal resection (HR: 0.91; 95% CI: 0.51-1.64; p = 0.76) was not significantly protective. Tumor location was not associated with overall survival (p = 0.16).
Discussion
Surgical patients with GBM who had a prior history of asthma or hypercholesterolemia had a significantly higher relative risk of mortality in multivariable analysis. Sex, race, and other medical comorbidities were not significantly associated with survival in this study. The poor prognosis of patients with GBM following diagnosis likely negates the hazardous effects of other medical comorbidities on survival. Many of such other diseases require years to cause fatal complications or contribute otherwise to earlier death.
One hypothesis for these findings is that there is a unique interaction between glioblastoma and these comorbidities. The pathophysiology behind asthma and hypercholesterolemia could influence the progression or development of GBM. Prior studies have found that patients with atopic diseases including allergies, eczema, and www.nature.com/scientificreports www.nature.com/scientificreports/ asthma have a decreased susceptibility to grade II and III gliomas and improved prognosis 26 . It has been shown that there is an inverse relationship between serum IgE levels and risk of glioma, and high amounts of mast cells have been detected in GBM tissues 27, 28 . Gohar et al. 28 linked certain IL-4Rα and IL-13 alleles to increased glioma susceptibility, and found the IL-4Rα AA genotype in GBM patients was associated with prolonged survival. A 2011 study by Scheurer et al. 29 found that those with a self-reported history of asthma/allergies and regular anti-inflammatory/NSAID use had a protective association with development of GBM, but there was no significant effect of regular antihistamine use on risk of GBM. A later study by Amirian et al. 30 revealed that regular antihistamine use in patients with self-reported asthma/allergy history was associated with increased risk of glioma, but without any observed effect on survival. Atopy is a disease of the immune system, and the immunologic Table 3 . Hazard ratios and confidence interval of individual-characteristic analyses adjusted for known cofounders. All analyses controlled for age, EOR, and tumor location. CI = Confidence Interval.
properties of GBM have been well-described 31 . It is reasonable to suspect that systemic diseases affecting the immunologic and inflammatory responses would have an effect on GBM development and prognosis. Perhaps those individuals with asthma have lesser risk of developing glioma, but are prone to more aggressive tumors or a worse clinical course when the tumor does emerge, which is plausible given the results of this study. It could also be that individuals with atopic diseases are less likely to develop secondary GBM arising from low-grade glioma, due to the previously-reported decreased susceptibility to lower-grade gliomas in these patients. Since primary GBM has a worse prognosis than secondary GBM this could explain the poorer survival seen in this sample. The relationship between atopy and GBM is actively being researched, and the relationship between asthma and overall survival in particular needs additional evidence.
There is less research on the relationship between hypercholesterolemia and GBM. Studies have shown the importance of cholesterol on GBM cell survival 32 . The effect of statin use on GBM has been better studied with data suggesting statins reduce risk of seizure prior to diagnosis, but do not significantly affect survival following diagnosis 33 . A study by Gaist et al. 34 demonstrated a dose-dependent survival benefit in those taking statins prior to diagnosis of GBM. This suggests that the level of control or treatment of hypercholesterolemia at the time of diagnosis may be an underlying factor explaining our observed relationship between hypercholesterolemia and overall survival.
Another hypothesis to explain the association between asthma and hypercholesterolemia and decreased survival is that these diseases could be fatal or lead to organ failure within a short time frame. Asthma is associated with increased post-operative pulmonary complications, including infection, asthma exacerbation, and acute respiratory failure 35 . Beyond the post-operative period, asthma still remains an immediate threat to life due to pneumonia and/or acute respiratory failure 36 . Hypercholesterolemia was associated with poorer overall survival within this study, but an explanation for these findings remains unclear. Hypercholesterolemia is related to myocardial infarction and other acute vascular events that can be rapidly fatal especially within the acute post-operative period. It would be expected that a history of heart disease and stroke would exhibit a similar relationship as hypercholesterolemia with overall survival, which was not observed within this study.
Prior studies evaluating comorbidities and long-term survival in patients with GBM have focused on a limited number of comorbid conditions, primarily diabetes mellitus 19, 37 . Additionally, the usual risk of mortality associated with hypertension, diabetes, stroke, and heart disease may be overcome by the drastically higher rate of mortality of patients within our sample population. It could be that individuals in our study with these diagnoses, which would reasonably be expected to cause many of the same acute vascular events as hypercholesterolemia, were already well-treated following prior diagnoses and thus did not experience these complications after their diagnosis of GBM. The other comorbidities measured in our sample, such as arthritis, incontinence, seizures, migraines, depression/anxiety, and thyroid disease, may increase the comorbid burden and poorer overall health status of patients, but would not be expected to increase the risk of mortality within the shortened life expectancy of patients presenting with GBM.
In our study, the observed probability of survival at 6-, 12-, 18-, and 24-months was 71%, 50%, 34%, and 26%, respectively, which is consistent with estimates of median survival from previous studies 2, 3 . There was a clear male predominance amongst patients who presented to our institution with GBM, which has been demonstrated in nationwide samples 2, 7 . In controlling for surgical EOR and age, we saw that complete resection and near total resection both were associated with significantly longer survival time when compared to biopsy alone, while subtotal resection was not significantly protective. This finding is consistent with previous studies suggesting the survival benefit of complete resection 7, 18 . Increasing age was associated with decreased survival, which has been repeatedly demonstrated in the literature 9, 10 . Tumor location was not associated with overall survival. Prior www.nature.com/scientificreports www.nature.com/scientificreports/ research has demonstrated that tumor location influences overall survival via surgical approaches, oncological management, and the ability to pursue surgical resection 25 . Our findings could be explained by not stratifying our tumor locations based on eloquence, or by preselecting surgical candidates based on those whose tumors were more amenable to surgery and underwent resection rather than conservative management alone.
Limitations. Limitations of this study include its retrospective nature and power. The sample size is comparable to other single-institution studies, although there was a limited sample size for subgroups for some comorbidities 5, 19 . This sample has a higher proportion of nonwhite patients compared to other studies on glioblastoma patients in the literature 2 . This may account for some of the divergence in findings and also may improve the applicability of these findings to medical centers with diverse patient populations. We did not evaluate tumor biomarkers, such as MGMT, IDH1/2, P53, EGFR, and PTEN, that are commonly related to overall survival, as these were not consistently available at the time of presentation to our institution for this study sample (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . VCU is an academic medical center with a large referral base, thus patients in the sample may have been diagnosed with a brain mass at an outside facility before coming to VCU for treatment. In addition, the 9% of patients who were censored at the date of their last clinic visit could have survived for significant amount of time afterwards, which would not be captured in this dataset. Lastly, we did not assess the underlying cause of death for each patient, which could further delineate whether progression of disease or other medical comorbidities were the attributable factor for mortality within this patient population. future directions. Future research with larger sample sizes using prospective or multi-institutional design would be valuable for investigating comorbid predictors of survival in GBM. Specifically, the underlying pathophysiology for asthma or hypercholesterolemia in relation to GBM should be investigated to understand how each disease process alters the overall length of survival. Properly treated hypercholesterolemia or asthma could potentially alter prognoses when compared to untreated disease in this population. The effects of lipid-lowering and asthma/allergy medications on the natural history, progression, and survival of patients with GBM is one possible avenue of further investigation. An examination of tumor markers present in patients with history of asthma or hypercholesterolemia could be useful in assessing potential mechanisms for differences in prognosis of these patients.
conclusions
GBM is an aggressive and prevalent primary CNS tumor with unfavorable overall survival and few known prognostic factors. This study demonstrates that, in addition to patient age and decreased extent of resection, history of asthma and hypercholesterolemia are each associated with a worse prognosis in GBM. Further research should establish the interactions of the pathophysiology of these diseases with glioblastoma and whether or not optimal medical control of asthma and hypercholesterolemia provides survival benefit. Recognizing and ensuring that comorbid conditions are adequately treated remains essential in the treatment of patients with GBM.
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